PHARMACOKINETICS OF THE NEW HEPATITIS C VIRUS NS3 PROTEASE INHIBITOR NARLAPREVIR FOLLOWING SINGLE-DOSE USE WITH OR WITHOUT RITONAVIR IN PATIENTS WITH LIVER CIRRHOSIS ArticleIsakov V., Koloda D., Tikhonova N., Krasavina E., Samsonov M., Kikalishvili T., Lekishvili K., Malaya I., Ryska M., Tolkacheva V.Antimicrobial Agents and Chemotherapy. Том 60. 2016.
